Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".
作者信息
Yim Sun Young, Lee Sung Hwan, Kim Ji Hoon, Lee Sunyoung S, Kaseb Ahmed O, Lee Ju-Seog
机构信息
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
出版信息
Clin Mol Hepatol. 2025 Jan;31(1):e84-e86. doi: 10.3350/cmh.2024.0830. Epub 2024 Oct 7.
Abstract
摘要
相似文献
1
Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".致关于“基因组生物标志物预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应：来自IMbrave150试验的见解”的编辑评论2
Clin Mol Hepatol. 2025 Jan;31(1):e84-e86. doi: 10.3350/cmh.2024.0830. Epub 2024 Oct 7.
2
Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial".致关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论1的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e81-e83. doi: 10.3350/cmh.2024.0829. Epub 2024 Oct 7.
3
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".预测晚期肝细胞癌组织中联合免疫治疗反应的转录组特征：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):308-310. doi: 10.3350/cmh.2024.0726. Epub 2024 Aug 30.
4
Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".致编辑的信：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信
Clin Mol Hepatol. 2025 Jan;31(1):e110-e112. doi: 10.3350/cmh.2024.0828. Epub 2024 Oct 2.
5
Reply to correspondence on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".对关于“预测肝细胞癌患者对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信的回复
Clin Mol Hepatol. 2025 Jan;31(1):e121-e122. doi: 10.3350/cmh.2024.0886. Epub 2024 Oct 11.
6
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".使用免疫检查点抑制剂治疗肝细胞癌的个性化方法：关于“预测肝细胞癌对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
7
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.预测肝细胞癌患者对阿替利珠单抗联合贝伐珠单抗免疫治疗反应的基因组生物标志物：来自 IMbrave150 试验的见解。
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
8
Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823].《肝细胞癌中预测阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解》勘误 [《临床分子肝病学》2024年；30:807 - 823]
Clin Mol Hepatol. 2025 Apr;31(2):669-670. doi: 10.3350/cmh.2024.0333e. Epub 2025 Feb 27.
9
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.阿替利珠单抗联合贝伐单抗用于不符合IMbrave150纳入标准的不可切除肝细胞癌患者的早期反应及安全性
Hepatol Res. 2021 Sep;51(9):979-989. doi: 10.1111/hepr.13693. Epub 2021 Jul 20.
10
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
本文引用的文献
1
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".使用免疫检查点抑制剂治疗肝细胞癌的个性化方法：关于“预测肝细胞癌对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
2
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.预测肝细胞癌患者对阿替利珠单抗联合贝伐珠单抗免疫治疗反应的基因组生物标志物：来自 IMbrave150 试验的见解。
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
3
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.个性化新抗原疫苗联合帕博利珠单抗治疗晚期肝细胞癌的 1/2 期临床试验。
Nat Med. 2024 Apr;30(4):1044-1053. doi: 10.1038/s41591-024-02894-y. Epub 2024 Apr 7.
4
Recent advances in the management of hepatocellular carcinoma.肝细胞癌治疗的最新进展。
Clin Mol Hepatol. 2024 Jan;30(1):1-15. doi: 10.3350/cmh.2023.0125. Epub 2023 Jul 21.
5
Methods and applications for single-cell and spatial multi-omics.单细胞和空间多组学的方法和应用。
Nat Rev Genet. 2023 Aug;24(8):494-515. doi: 10.1038/s41576-023-00580-2. Epub 2023 Mar 2.
6
Radiomics: A review of current applications and possibilities in the assessment of tumor microenvironment.放射组学：肿瘤微环境评估中当前应用和可能性的综述。
Diagn Interv Imaging. 2023 Mar;104(3):113-122. doi: 10.1016/j.diii.2022.10.008. Epub 2022 Oct 22.
7
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.炎症和非炎症 HCC 分类：一种修正的免疫基因组分类。
Gut. 2023 Jan;72(1):129-140. doi: 10.1136/gutjnl-2021-325918. Epub 2022 Feb 23.
8
Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.免疫细胞在乙型肝炎病毒相关性肝细胞癌患者中的作用。
Int J Mol Sci. 2021 Jul 27;22(15):8011. doi: 10.3390/ijms22158011.
9
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
10
Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis.单细胞技术在肝脏病学中的应用：对肝脏生物学和疾病发病机制的新认识。
Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):457-472. doi: 10.1038/s41575-020-0304-x. Epub 2020 Jun 1.
Zotero 插件